Key result
Novel oral anticoagulants, such as dabigatran, rivaroxaban, and apixaban, provide alternatives to warfarin for stroke prevention in nonvalvular atrial fibrillation without requiring INR monitoring.
Why the study?
Do novel oral anticoagulants prevent stroke in patients with nonvalvular atrial fibrillation?
Population
Patients with nonvalvular atrial fibrillation
Comparison
Novel oral anticoagulants vs Warfarin
Design
Review
Authors
Loading...
Supports NOAC alternatives to warfarin in nonvalvular AF without INR monitoring; leaves open optimal agent selection in specific populations.
Do novel oral anticoagulants prevent stroke in patients with nonvalvular atrial fibrillation?
This review summarizes the pharmacological properties, clinical trial data, and practical considerations for using novel oral anticoagulants as an alternative to warfarin for stroke prevention in nonvalvular atrial fibrillation.
Contractor et al. (2013) conducted a review in Atrial fibrillation. Novel oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban) vs. Warfarin was evaluated. Novel oral anticoagulants, such as dabigatran, rivaroxaban, and apixaban, provide alternatives to warfarin for stroke prevention in nonvalvular atrial fibrillation without requiring INR monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: